Pseudo Target Amplification Diagnostics

伪目标扩增诊断

• 批准号: 7322835
• 负责人: ROBERT W HENKENS
• 金额: $ 14.12万
• 依托单位: ALDERON BIOSCIENCES, INC.
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7322835
• 关键词: Accounting; Antibiotics; Antiviral Agents; Arts; Binding; Biological Assay; Categories; Cause of Death; Cessation of life; Clinical; Communicable Diseases; Condition; Country; Data; Detection; Development; Diagnosis; Diagnostic; Diagnostic tests; Disasters; Disease; Elements; Emerging Communicable Diseases; Goals; Health; Human; Influenza; Investigation; Laboratories; Legal patent; Location; Marketing; Measurement; Measures; Medical Research; Medical Surveillance; Methods; Molecular; Molecular Probes; National Institute of Allergy and Infectious Disease; Nucleic Acid Amplification Tests; Nucleic Acid Probes; Output; Production; Public Health; Public Health Applications Research; Public Hospitals; RNA Probes; RNA Sequences; Research; Reverse Transcriptase Polymerase Chain Reaction; Robotics; Sampling; System; Technology; Testing; Time; United States; Vaccination; Virion; Virus Diseases; Work; base; biodefense; cost; design; disability; flu; improved; influenza epidemic; influenza virus strain; influenzavirus; innovation; instrument; novel strategies; nucleic acid detection; pandemic disease; pandemic influenza; pathogen; point of care; programs; response; sensor; tool; viral RNA

DESCRIPTION (provided by applicant): The National Institute of Allergy and Infectious Disease has called for better tools for the detection and diagnosis of emerging and re-emerging infectious diseases such as influenza. The need is for tests that are practical and affordable for use at point-of-care and near point-of-care settings, such as local public health departments, underdeveloped countries, and disaster situations anywhere. This problem is particularly important for human infectious diseases for which good molecular (DNA/RNA) tests do not exist for use at point-of-care and at other underserved locations. Alderon Biosciences, Inc. proposes to develop and test an innovative electrochemical assay for measuring and distinguishing viral RNA of flu types and subtypes that are major health threats. The technical innovation involves a new approach for highly sensitive target detection based on electrochemical sensors that is called Pseudo- Target-Amplification (PTA). The instrument and sensor elements will be designed and developed so that viral RNA measurement will use less assay time, fewer steps, and much lower set-up and per-result cost than the current state-of-the-methods such as real time RT-PCR. The expected result is an electrochemical assay technology that will accurately measure viral RNA targets down to 100-molecules/ mL sample for use in the diagnosis, treatment, and control of viral infections. Preliminary investigation indicates a significant market for the proposed technology in research and public health applications that is rapidly growing over the next three- to five-year period as the demand increases for simpler, more accessible, and widely applicable molecular tools for measurement of viral RNA targets in clinical samples. Alderon's new tool for rapid and low-cost detection of nucleic acids of pathogens is envisioned as a powerful new tool for Public Health and Biodefense applications. Its development would allow more rapid and effective response to enable health labs around the world to more readily carry out flu diagnosis and surveillance, reducing heath costs through faster and lower-cost determination of causative pathogens. Improved diagnostics for influenza will promote more prudent and effective use of antiviral drugs and avoid indiscriminate use of antibiotics. We estimate the near term medical research and public health market for eSystem detection systems to be in excess of $6 million per year.

描述（由申请人提供）：国家过敏和传染病研究所呼吁提供更好的工具来检测和诊断新出现和再出现的传染病，如流感。需要的是实用和负担得起的检测方法，以便在医疗点和医疗点附近使用，例如在当地公共卫生部门、不发达国家和任何地方的灾害情况下使用。这一问题对人类传染病尤其重要，因为在护理点和其他服务不足的地点没有良好的分子（DNA/RNA）检测方法。Alderon Biosciences, Inc.提议开发和测试一种创新的电化学测定方法，用于测量和区分对健康构成主要威胁的流感类型和亚型的病毒RNA。该技术创新涉及一种基于电化学传感器的高灵敏度目标检测新方法，即伪目标放大（PTA）。仪器和传感器元件将被设计和开发，使病毒RNA测量将使用更少的分析时间，更少的步骤，更低的设置和每个结果的成本比目前的方法，如实时RT-PCR。预期的结果是一种电化学分析技术，可以准确地测量病毒RNA靶点至100分子/ mL样品，用于病毒感染的诊断、治疗和控制。初步调查表明，随着对用于测量临床样本中病毒RNA靶点的更简单、更容易获得和广泛适用的分子工具的需求增加，该技术在研究和公共卫生应用方面的重要市场将在未来三到五年内迅速增长。